Rashmi Koul

Rashmi Koul

Auto-generated profile, based on publicly available information

Rashmi Koul

CancerCare Manitoba, Winnipeg, MB, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2020 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PDF file
SRShrinivas Rathod
Shrinivas Rathod
ADArbind Dubey
Arbind Dubey
BBBashir Bashir
Bashir Bashir
GSGokulan Sivananthan
Gokulan Sivananthan
ALAhmet Leylek
Ahmet Leylek
RKRashmi Koul
Rashmi Koul
As COVID-19 pandemic continues to explode, cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic radiation regimen in a Canadian province with 4 new R’s of COVID era.

27 August 2015 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
Patricia TaiPatricia Tai
Patricia Tai
ADArbind Dubey
Arbind Dubey
MSMuhammad Salim
Muhammad Salim
KVKhanh Vu
Khanh Vu
RKRashmi Koul
Rashmi Koul
Background: When patients with cranial glioblastoma develop weakness, a rare differential diagnosis is spinal metastases. Methods: Chart and literature reviews were performed. Results: The reported patient had delayed onset spinal drop metastasis that was only detected by magnetic resonance imaging (MRI). A 48-year-old patient had supratentorial glioblastoma, treated with radiotherapy (RT) and concurrent temozolomide followed by six cycles of adjuvant temozolomide. Four years after completion of all treatments (62 months from initial presentation), he developed low backache and weakness in both legs. Positron emission tomography/computed tomography scans demonstrated intracranial recurrence only. Spinal drop metastases were detected only by MRI scan. Local spinal RT 40 Gy in 20 fractions with concurrent and maintenance temozolomide were given. Because of disease progression after nine cycles of temozolomide, systemic therapy was changed to bevacizumab, which greatly improved his symptoms for 4 months before deterioration of mental status. He is still alive with disease at 22 months after diagnosis of spinal metastases (84 months from initial glioblastoma diagnosis). Conclusions: MRI is the diagnostic imaging of choice for spinal metastases. This illustrative case of delayed-onset spinal metastases shows unusual slow progression. Local RT, temozolomide, and targeted therapy may improve survival. This illustrative case is the first report of bevacizumab as a second-line therapy in drop metastasis of glioblastoma.

1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
ADA. Dubey
A. Dubey
KJKate Johnson
Kate Johnson
DSD. Sasaki
D. Sasaki
CHC. Harris
C. Harris
AEA. Egtberts
A. Egtberts
RKR. Koul
R. Koul
The use of 3D printing for medical use is well established and has been utilized in clinical practices ranging from surgical planning to individualized medical implants. Three-dimensional printing has been implemented at our institution to create customized treatment accessories such as shielding and immobilization. In order to use 3D printing, the topography of the patient must first be acquired. We have previously achieved this using resource intensive methods, such as a plaster mold or a CT scan. Recently, 3D scanners have been developed which are low cost (∼$500), and can quickly acquire both the topographical and texture information of a patient. These scanners use methods such as structured light in order to construct accurate 3D models in minutes. We have characterized a structured light 3D scanner (3D Systems Sense), and have designed and built a scanning gantry in order to assess the clinical viability of this technology.

1 October 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
ADA. Dubey
A. Dubey
ASA.M. Sharma
A.M. Sharma
DSD. Sasaki
D. Sasaki
DRD. Rickey
D. Rickey
PMP. McGeachy
P. McGeachy
RKR. Koul
R. Koul
Purpose/Objective(s) The use of 3D printer technology to create bolus for radiotherapy (RT) is greatly increasing. At our center, we use an optical scanner to obtain patient surface anatomy images which are used to 3D print a rigid bolus for patients undergoing RT for sarcoma or skin cancer. This bolus is superior to conventional bolus as it produces a more accurate fit with less air gaps, especially in complex treatment areas. At our institution and many others 3D printed bolus is becoming more common and so we set out to analyze time effectiveness and explore staff and patient perception of utilizing 3D printer technology. Materials/Methods We ran mock RT simulation sessions for skin cancer of the nose and ear using a staff volunteer as a mock patient. Each mock session had a time recorded run through of the standard fabrication and set up for RT using a conventional bolus compared to optical scan and set up time for 3D printed bolus, in both cases involving radiation therapists, physicists, and physicians. A ten question survey was developed to explore patient and staff perceptions of utilizing 3D printer technology. Responses were graded from 1 – 5. Surveys were administered pre and post-mock and average scores were computed. Results Fabrication time for creation of conventional nose bolus was 11 minutes (m) 35 seconds (s) compared to 10m 43s for 3D printing scan time, a savings of 1m 8s (10% time savings). Set up time for conventional nose bolus was 46s, compared to 14s for the 3D printed bolus, savings of 34 seconds (74% time savings). Fabrication time for creation of conventional ear bolus was 9m 12s compared to 4m 40s for 3D printing scan time, a savings of 4m 32s (44% time savings). Set up time for conventional ear bolus was 2m 7s, compared to 35s for the 3D printed bolus, as savings of 1m 32s (72% time savings). Average survey score for nose bolus fabrication pre-mock was 4.10 and 4.22 post-mock, an improvement of 0.12 (2%). Average score for nose bolus set up was 4.04 pre-mock and 4.66 post-mock, an improvement of 0.62 (12%). Average survey score for ear bolus fabrication pre-mock was 4.06 and 4.30 post-mock, an improvement of 0.24 (5%). Average score for ear bolus set up was 4.31 pre-mock and 4.81 post-mock, an improvement of 0.50 (10%). Conclusion We have shown, by using a simple mock simulation technique, a significant amount of time can be saved by utilizing 3D printer technology to create bolus. This is significant because it can save costs and valuable patient time when applied on a larger scale. We also showed that staff and patient perceptions in the use of 3D printer technology improved after they were exposed to the mock simulation. This suggests an eagerness by both staff and patients to adopt this readily available technology. Based on study findings and the many other advantages of 3D printed bolus for RT, we recommend that this technology be used more commonly at cancer centers around the world.

1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PDF file
ADArbind Dubey
Arbind Dubey
APAlok Pathak
Alok Pathak
ASAnkur Sharma
Ankur Sharma
CHChad Harris
Chad Harris
DRDaniel Rickey
Daniel Rickey
RKRashmi Koul
Rashmi Koul
Dose escalation of non-small cell lung cancer is typically limited by increasing risk of severe adverse events, including radiation pneumonitis (RP). Recent studies have demonstrated a relationship between a CBCT derived marker (CDM) and lung density changes on follow up imaging. This study investigates the relationship between a density-based CBCT image marker and symptomatic radiation pneumonitis. Methods and Materials: CDMs were extracted for NSCLC patients treated definitively (> 54 Gy) with fractionated radiotherapy between 2011 and 2013. The CDM was defined as the proportion of normal lung voxels receiving 20-60 Gy that demonstrated an intensity increase between the first and tenth fraction CBCT, as previously described. Only voxels with an intensity change greater than a defined noise threshold were included. All images were registered into a common volume using an intensity-based deformable image registration algorithm in the Elastix toolbox. All other image analysis was implemented in Matlab 2010b. RP was determined from prospective clinical records and reviewed retrospectively from the electronic patient record, as scored by the treating oncologists at follow up visits as per CTCAE v 4.0. Dosimetric parameters extracted included mean lung dose and volume of lung receiving 20 Gy (V20). Correlation of dosimetric parameters and the CDM to RP events was assessed by Spearman's rank correlation coefficient and multivariate logistical regression. Results: After excluding patients without dose or CBCT objects, 65 patients were identified and CDM extracted. In those patients, the prescription dose range was 54-74 Gy, mean lung dose range was 13-23 Gy and V20 range was 3.4-38%. The number of voxels with an intensity change greater than the noise level ranged from 0-74.5% (mean 5.3%). Symptomatic RP (≥ Grade 2) occurred in 26.1% of patients of these patients. Spearman's rank correlation demonstrated significant association between mean lung dose and V20 with symptomatic radiation pneumonitis (p = 0.044 and p = 0.036 respectively), whereas the CBCT marker was not correlated (p = 0.609). Univariate logistic regression of mean lung dose and the CBCT marker was not significantly correlated with symptomatic RP (p = 0.090 and p = 0.821 respectively). Multivariate logistic regression with mean lung dose and the CBCT marker was not significant (p = 0.077). Conclusions: One previously described density-related CDM was not correlated with RP in this dataset. Further research is required to characterize the role of imaging markers in predicting radiation pneumonitis.

23 September 2022 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JCJui Chih Cheng
Jui Chih Cheng
SVSankar Venkataraman
Sankar Venkataraman
NANaseer Ahmed
Naseer Ahmed
LTLawrence Tan
Lawrence Tan
K Biniam Kidane
Biniam Kidane
JKJulian Kim
Julian Kim